Status:
RECRUITING
Application of Remimazolam Combined With Esketamine in Painless Gastroscopy and Colonoscopy in Elderly Patients
Lead Sponsor:
Harbin Medical University
Collaborating Sponsors:
First Affiliated Hospital of Harbin Medical University
Conditions:
Gastrointestinal Disease
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
The objective of this clinical trial is to assess the feasibility of the remimazolam combined with esketamine OFA (opioid-free anesthesia) protocol for painless gastroscopy and colonoscopy in elderly ...
Detailed Description
Elderly patients undergoing painless gastroenteroscopy were randomly divided into remazolam + esketamine group (RE group) and remazolam + remifentanil group (RR group). In RE group, anesthesia inducti...
Eligibility Criteria
Inclusion
- Patients undergoing painless gastroenteroscopy in outpatient clinics;
- aged 65 years and above;
- American Society of Anesthesiologists (ASA) grades I - III.
Exclusion
- Patients with abnormal liver or kidney function;
- known respiratory or endocrine diseases;
- Patients with uncontrolled hypertension and NYHA classification Ⅲ-Ⅳ;
- Taking monoamine oxidase inhibitors, sedatives, analgesics, hypnotics, antipsychotics, antiemetics or antidepressants;
- Addiction to tobacco and alcohol;
- Patients allergic to the investigational drug;
- expected difficult airway;
- Body mass index (BMI) \>35kg/m\^2;
- Have participated in other clinical trials within the past three months;
- Patients with psychosocial illness or cognitive dysfunction and inability to cooperate or communicate.
Key Trial Info
Start Date :
March 14 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2028
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT07002801
Start Date
March 14 2025
End Date
January 1 2028
Last Update
June 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150001